Company Overview and News

 
Indian Hume Pipe receives order worth Rs 221 cr

2018-09-18 thehindubusinessline
Indian Hume Pipe Company has received Letter of Acceptance for ₹221.72 crore from Madhya Pradesh Jal Nigam Maryadit (A Government of Madhya Pradesh Undertaking) for EPC work of various components of Indwar-1 Multi Village Rural Water Supply Scheme at Umaria and Katni on turnkey basis, including trial run & maintenance of the entire scheme for 10 years.
INDIANHUME 504741

4
An evening walk down Dalal Street | Crude surge, weak financials weigh on Sensex, Nifty gives up 11,300

2018-09-18 moneycontrol
Bearish momentum continued on D-Street for the second consecutive day on Tuesday as a sharp selloff in the last hour dragged the market. The Nifty breached 11,300-mark and ended below it, while the Sensex closed around 300 points lower.
YESBANK 539336 HINDUNILVR 532648 YYBKY 532401 VIJAYABANK GUJGAS 532121 INDIANHUME 500696 500570 504741 TATAMOTORS DENABANK SBAZ TTM

 
Indian Hume Pipe rises 4% after company bags order worth Rs 221cr

2018-09-18 moneycontrol
Share price of Indian Hume Pipe Company rose 4.7 percent intraday Tuesday as company bagged order from Madhya Pradesh government.
INDIANHUME 504741

 
Land development may boost Indian Hume Pipe

2018-09-10 thehindubusinessline
Indian Hume Pipe Company on Monday signed a Memorandum of Understanding with Kalpataru Gardens Pvt Ltd, the Developer, (a wholly-owned subsidiary of Kalpataru) for development of the company’s land at Vadgaon, Pune. The company has given the Power of Attorney to the Developer for obtaining approvals, sanctions, permissions and NOCs relating to the project. Shareholders will closely monitor the execution and further development of the project.
INDIANHUME 504741

4
An evening walk down Dalal Street | Sensex, Nifty start week on a negative note amid weak rupee, global tensions

2018-09-10 moneycontrol
It’s not a result that the bulls would have anticipated, considering the pullback it had on September 7, 2018. A weak rupee, which fell to record lows of 72.67 per US dollar weighed heavily on indices. The Indian currency saw weak moves following macro concerns on the domestic front along with having spillover effects of a selloff in emerging market currencies too.
INDIANHUME 500570 504741 TATAMOTORS TTM

 
Indian Hume Pipe gains 8% as Co signs MoU with Kalpataru Gardens to develop Pune land

2018-09-10 moneycontrol
Shares of Indian Hume Pipe Company gained 8.5 percent intraday Monday as company signed MoU with Kalpataru Gardens for development of land at Vadgaon, Pune.
INDIANHUME 504741

 
Kalpataru in deal with Indian Hume Pipe to develop 15 acre Pune land

2018-09-10 livemint
Mumbai: Mumbai-based real estate firm Kalpataru Ltd has entered into a joint development agreement with pipe manufacturer Indian Hume Pipe Co. Ltd, to develop a 15-acre land parcel for a residential project in suburban Pune.
GODREJPROP INDIANHUME 533150 504741

 
Indian Hume Pipe bags Rs 256 cr order

2018-08-20 thehindubusinessline
Indian Hume Pipe Company has received a work order of ₹256.19 crore from the Tamil Nadu Water Supply & Drainage Board, Coimbatore. The order is for providing combined water supply scheme to Alampalayam Town Panchayat, Padaveedu Town Panchayat including 669 rural habitations in Pallipalayam and Tiruchengode Unions in Namakkal District, and Sankari Town Panchayat in Salem District with river Cauvery as source.
INDIANHUME 504741

 
Indian Hume Pipe surges 6% on order win worth Rs 256cr

2018-08-20 moneycontrol
Share price of Indian Hume Pipe Company surged 6 percent intraday Monday as company won a new order worth Rs 256 crore.
INDIANHUME 504741

 
World’s Biggest Toilet-Building Spree Is Under Way in India - Bloomberg

2018-08-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JSGRY SOMANYCERA KAJARIACER HINDUNILVR 531548 CERA JSGCF RB 5938 532443 INDIANHUME 500233 500696 504741

 
World’s biggest toilet-building spree under way in India

2018-07-31 malaymail
NEW DELHI, July 31 — India is on the greatest toilet-building spree in human history, and it’s a windfall for companies.
JSGRY INDIANHUME 500696 HINDUNILVR JSGCF RB 5938 504741

22
Market Live: Sensex in the red, rupee sinks 35 paise; BJP leads in Karnataka but away from half-way mark

2018-05-15 moneycontrol
Earnings: Pharma major Lupin has posted a loss of Rs 783.5 crore for the quarter ended March 2018, due to one-time loss of Rs 1,464.3 crore on Gavis Group acquisition.
PWQFY 539150 500325 EMAMIINFRA BHUSANSTL RELIANCE PNCINFRA 532810 539437 500470 IDFCBANK RIGD 500570 SNOWMAN TATAMOTORS 500055 RLNIY INDIGO IBN 532605 JBMA 538635 539448 PFC ICICIBANK 533218 ZANDUREALT TTST INDIANHUME TATASTEEL TATLY 532174 504741 506720 TTM

 
Indian Hume Pipe slips 4% on cancellation of LoA worth Rs 578 crore

2018-05-15 moneycontrol
Shares of Indian Hume Pipe Company declined 4 percent intraday Tuesday as company received cancellation of letter of acceptance from Madhya Pradesh Jal Nigam Maryadit.
INDIANHUME 504741

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...